Interest of Levosimendan in Reducing Weaning Failures of ExtraCorporeal Life Support - ECLS

Inclusion Criteria: * adult patient * patient or person responsible for the patient has given written consent * patient with acute circulatory heart failure under ECLS * patient meeting criteria for ECLS withdrawal * ECLS flow rate at 1.0-1.5l/min and/or ECLS pump rpm ≤ 1500 rpm * LVEF \> 20% in cardiac ultrasound and aortic ITV \> 10 cm * VIS score ≤ 10 * Arterial lactates ≤ 2 mmol/l * Right ventricular outflow tract shortening fraction \> 30% * Basal diameter at the tricuspid telediastolic ring of the right ventricle \< 35 mm * Fraction of inspired oxygen combined between ventilator and ECLS \< 80% * ECLS withdrawl scheduled within 48 hours * Absence of an initial or progressive infectious episode (no planned introduction of antibiotic therapy within 48 hours prior to inclusion) Exclusion Criteria: * Patient with hepatic insufficiency: cytolysis at least 20 times normal * Drug intoxication and attempted suicide * Patient with a contraindication to the use of levosimendan: * hypersensitivity to the active substance or any of the excipients * severe hypotension and ventricular tachycardia * significant mechanical obstructions affecting ventricular filling and/or ejection * severe renal failure (creatinine clearance \< 30 ml/min) * severe liver failure (TP\<50%) * history of torsades de pointes * Patient with a contraindication to the use of CERNEVIT®: * hypersensitivity to active substances, in particular to vitamin B1 or to one of the excipients or to soy protein products or to peanut protein products * hypervitaminosis to any vitamin contained in this formulation * severe hypercalcemia, hyper calciuria, tumour, bone metastasis, primary hyperparathyroidism, granulomatosis * patient not affiliated to or not benefiting from national health insurance * patient subject to legal protection (curatorship, guardianship) * patient subject to limited judicial protection * pregnant, parturient or breastfeeding woman